O Shaughnessy Asset Management LLC Buys 1,610 Shares of Insulet Co. (NASDAQ:PODD)

O Shaughnessy Asset Management LLC lifted its position in Insulet Co. (NASDAQ:PODD) by 43.7% during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 5,291 shares of the medical instruments supplier’s stock after buying an additional 1,610 shares during the period. O Shaughnessy Asset Management LLC’s holdings in Insulet were worth $1,381,000 as of its most recent SEC filing.

Other large investors have also made changes to their positions in the company. Public Sector Pension Investment Board increased its holdings in shares of Insulet by 14.8% during the third quarter. Public Sector Pension Investment Board now owns 3,099 shares of the medical instruments supplier’s stock valued at $721,000 after acquiring an additional 400 shares in the last quarter. Captrust Financial Advisors lifted its holdings in Insulet by 5.1% in the third quarter. Captrust Financial Advisors now owns 1,760 shares of the medical instruments supplier’s stock valued at $410,000 after acquiring an additional 86 shares during the period. Janus Henderson Group PLC boosted its holdings in Insulet by 14.6% during the third quarter. Janus Henderson Group PLC now owns 7,335 shares of the medical instruments supplier’s stock worth $1,706,000 after buying an additional 935 shares in the last quarter. Investment Management Corp of Ontario boosted its stake in shares of Insulet by 44.6% during the 3rd quarter. Investment Management Corp of Ontario now owns 2,271 shares of the medical instruments supplier’s stock worth $529,000 after acquiring an additional 700 shares in the last quarter. Finally, Integrated Wealth Concepts LLC boosted its position in Insulet by 1.7% during the third quarter. Integrated Wealth Concepts LLC now owns 2,561 shares of the medical instruments supplier’s stock worth $596,000 after purchasing an additional 42 shares in the last quarter.

Insider Transactions at Insulet

In other news, EVP Eric Benjamin sold 12,394 shares of the firm’s stock in a transaction that occurred on Tuesday, January 21st. The stock was sold at an average price of $280.00, for a total value of $3,470,320.00. Following the completion of the sale, the executive vice president now directly owns 11,383 shares of the company’s stock, valued at $3,187,240. This trade represents a 52.13 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Wayne A.I. Frederick sold 1,825 shares of the business’s stock in a transaction on Tuesday, March 25th. The stock was sold at an average price of $275.00, for a total transaction of $501,875.00. Following the sale, the director now owns 3,231 shares in the company, valued at $888,525. The trade was a 36.10 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders own 0.47% of the company’s stock.

Wall Street Analysts Forecast Growth

PODD has been the topic of several research analyst reports. TD Cowen lifted their target price on shares of Insulet from $264.00 to $324.00 and gave the company a “buy” rating in a research report on Friday, January 3rd. Piper Sandler upped their target price on Insulet from $285.00 to $310.00 and gave the company an “overweight” rating in a report on Friday, February 21st. Stifel Nicolaus raised their price target on shares of Insulet from $245.00 to $293.00 and gave the stock a “hold” rating in a report on Friday, February 21st. Raymond James reissued an “outperform” rating and set a $328.00 price objective (up from $294.00) on shares of Insulet in a research report on Friday, February 21st. Finally, StockNews.com lowered Insulet from a “buy” rating to a “hold” rating in a research report on Tuesday, March 4th. Four analysts have rated the stock with a hold rating and fourteen have given a buy rating to the company’s stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $292.06.

Insulet Trading Down 4.5 %

PODD opened at $245.26 on Friday. The company has a debt-to-equity ratio of 1.21, a quick ratio of 2.80 and a current ratio of 3.68. Insulet Co. has a one year low of $160.19 and a one year high of $289.46. The business’s 50-day simple moving average is $269.86 and its 200-day simple moving average is $259.70. The company has a market cap of $17.22 billion, a P/E ratio of 42.36, a PEG ratio of 3.62 and a beta of 1.30.

Insulet (NASDAQ:PODD) last posted its earnings results on Thursday, February 20th. The medical instruments supplier reported $1.15 EPS for the quarter, topping analysts’ consensus estimates of $1.00 by $0.15. Insulet had a return on equity of 24.46% and a net margin of 20.19%. The business had revenue of $597.50 million for the quarter, compared to analysts’ expectations of $582.02 million. As a group, equities research analysts expect that Insulet Co. will post 3.92 EPS for the current fiscal year.

Insulet Company Profile

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.